GLP1 and cancer: Friend or foe?

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages

  Vangoitsenhoven, Roman ^a,b   Mathieu, Chantal ^a,b   Van Der Schueren, Bart ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOXORUBICIN; DULAGLUTIDE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; NATEGLINIDE; PACLITAXEL; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; TASPOGLUTIDE;

APOPTOSIS; BLOOD PRESSURE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COLON CANCER; CYTOTOXICITY; GLUCAGON RELEASE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RELEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREATITIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH EMPTYING; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT DURATION;

ANIMALS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; NEOPLASMS; RECEPTORS, GLUCAGON;

EID: 84867407679     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0111     Document Type: Review

References (70)

1. Agerso H, Jensen LB, Elbrond B, Rolan P & Zdravkovic M 2002 The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 195-202. (doi:10.1007/s00125-001-0719-z)
2. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW et al. 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 869-875. (doi:10.2337/diacare.25.5.869)
3. Arzneimittelkommission der deutschen Ärzteschaft 2011 "Aus der UAW-Datenbank": pankreaskarzinome im zusammenhang mit Exenatid (Byetta®). Dtsch Arztebl 108 A-1080.
4. Baggio LL & Drucker DJ 2004 Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Practice & Research. Clinical Endocrinology & Metabolism 18 531-554. (doi:10.1016/j.beem.2004.08.001)
5. Ban K, Hui S, Drucker DJ & Husain M 2009 Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. Journal of the American Society of Hypertension 3 245-259. (doi:10.1016/j.jash.2009.04.001)
6. Bayliss WM & Starling EH 1902 The mechanism of pancreatic secretion. Journal of Physiology 28 325-353.
7. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H et al. 2010 Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151 1473-1486. (doi:10.1210/en.2009-1272)
8. Blomgren KB, Sundstrom A, Steineck G & Wiholm BE 2002 Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 25 298-302. (doi:10.2337/diacare.25.2.298)
9. Brubaker PL & Drucker DJ 2004 Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145 2653-2659. (doi:10.1210/en.2004-0015)
10. Bullock BP, Heller RS & Habener JF 1996 Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137 2968-2978. (doi:10.1210/en.137.7.2968)
11. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L & Group L-S 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 39-47. (doi:10.1016/S0140-6736(09)60659-0)
12. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S & Butler PC 2010 Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 53 21-26. (doi:10.1007/s00125-009-1556-8)
13. Cure P, Pileggi A & Alejandro R 2008 Exenatide and rare adverse events. New England Journal of Medicine 358 1969-1970 (discussion 1971-1972). (doi:10.1056/NEJMc0707137)
14. Currie CJ, Poole CD & Gale EA 2009 The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 1766-1777. (doi:10.1007/s00125-009-1440-6)
15. Denker PS & Dimarco PE 2006 Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 29 471. (doi:10.2337/diacare.29.02. 06.dc05-2043)
16. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA & Seeger JD 2011 A cohort study of acute pancreatitis in relation to exenatide use. Diabetes, Obesity & Metabolism 13 559-566. (doi:10.1111/j.1463-1326.2011.01376.x)
17. Drucker DJ & Goldfine AB 2011 Cardiovascular safety and diabetes drug development. Lancet 377 977-979. (doi:10.1016/S0140-6736(10)62299-4)
18. Drucker DJ, Mojsov S & Habener JF 1986 Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. Journal of Biological Chemistry 261 9637-9643.
19. Drucker DJ, Erlich P, Asa SL & Brubaker PL 1996 Induction of intestinal epithelial proliferation by glucagon-like peptide 2. PNAS 93 7911-7916. (doi:10.1073/pnas.93.15.7911)
20. Elashoff M, Matveyenko AV, Gier B, Elashoff R & Butler PC 2011 Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141 150-156. (doi:10.1053/j.gastro.2011.02.018)
21. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD 2005 Metformin and reduced risk of cancer in diabetic patients. BMJ 330 1304-1305. (doi:10.1136/bmj.38415.708634.F7)
22. Fehmann HC & Habener JF 1992 Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130 159-166. (doi:10.1210/en.130.1.159)
23. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D & Baron AD 2003 Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26 2370-2377. (doi:10.2337/diacare.26.8.2370)
24. Gallagher EJ & LeRoith D 2011 Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences 1243 54-68. (doi:10.1111/j.1749-6632.2011.06285.x)
25. Garg R, Chen W & Pendergrass M 2010 Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33 2349-2354. (doi:10.2337/dc10-0482)
26. Ghatei MA, Goodlad RA, Taheri S, Mandir N, Brynes AE, Jordinson M & Bloom SR 2001 Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Digestive Diseases and Sciences 46 1255-1263. (doi:10.1023/A:1010615429639)
27. Ghiglione M, Uttenthal LO, George SK & Bloom SR 1984 How glucagon-like is glucagon-like peptide-1? Diabetologia 27 599-600. (doi:10.1007/BF00276976)
28. Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM & Yeh MW 2012 Glucagon like peptide-1 receptor expression in the human thyroid gland. Journal of Clinical Endocrinology and Metabolism 97 121-131. (doi:10.1210/jc.2011-2407)
29. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG & Yee D 2010 Diabetes and cancer: a consensus report. Diabetes Care 33 1674-1685. (doi:10.2337/dc10-0666)
30. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE & Katz L 2010 Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes, Obesity & Metabolism 12 766-771. (doi:10.1111/j.1463-1326.2010.01231.x)
31. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH & Rorsman P 1998 Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47 57-65. (doi:10.2337/diabetes.47.1.57)
32. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, Poulsen SS&Holst JJ 2000 Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141 4013-4020. (doi:10.1210/en.141.11.4013)
33. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C & Dang NH 2008 The role of CD26/dipeptidyl peptidase IV in cancer. Frontiers in Bioscience 13 1634-1645. (doi:10.2741/2787)
34. Hegedus L, Moses AC, Zdravkovic M, Le Thi T & Daniels GH 2011 GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. Journal of Clinical Endocrinology and Metabolism 96 853-860. (doi:10.1210/jc.2010-2318)
35. Hjollund KR, Deacon CF & Holst JJ 2011 Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 54 2206-2208. (doi:10.1007/s00125-011-2168-7)
36. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML & Ulusoy NB 1997 Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. American Journal of Physiology 273 G920-G927.
37. Jura N, Archer H & Bar-Sagi D 2005 Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Research 15 72-77. (doi:10.1038/sj.cr.7290269)
38. 2+ release and exocytosis in pancreatic beta-cells. Journal of Biological Chemistry 278 8279-8285. (doi:10.1074/jbc.M211682200)
39. Kieffer TJ, McIntosh CH & Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 3585-3596. (doi:10.1210/en.136.8.3585)
40. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S , Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D et al. 2011 Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54 965-978. (doi:10.1007/s00125-010-2028-x)
41. Koehler JA & Drucker DJ 2006 Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 55 1369-1379. (doi:10.2337/db05-1145)
42. Koehler JA, Harper W, Barnard M, Yusta B & Drucker DJ 2008 Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Research 68 7897-7904. (doi:10.1158/0008- 5472.CAN-08-0029)
43. Koehler JA, Kain T & Drucker DJ 2011 Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 152 3362-3372. (doi:10.1210/en.2011-1201)
44. Korner M, Stockli M, Waser B & Reubi JC 2007 GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. Journal of Nuclear Medicine 48 736-743. (doi:10.2967/jnumed.106. 038679)
45. Kreymann B, Williams G, Ghatei MA & Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 1300-1304. (doi:10.1016/S0140-6736(87)91194-9)
46. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B & Rubinek T 2012 The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Research and Treatment 132 449-461. (doi:10.1007/s10549-011-1585-0)
47. Livolsi VA & Feind CR 1979 Incidental medullary thyroid carcinoma in sporadic hyperparathyroidism. An expansion of the concept of C-cell hyperplasia. American Journal of Clinical Pathology 71 595-599.
48. + currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. Journal of Biological Chemistry 278 52446-52453. (doi:10.1074/jbc.M307612200)
49. Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A et al. 2012 GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153 1538-1547. (doi:10.1210/en.2011-1864)
50. Masur K, Schwartz F, Entschladen F, Niggemann B & Zaenker KS 2006 DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regulatory Peptides 137 147-155. (doi:10.1016/j.regpep.2006.07. 003)
51. Matteucci E & Giampietro O 2009 Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Current Medicinal Chemistry 16 2943-2951. (doi:10.2174/092986709788803114)
52. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE & Butler PC 2009 Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58 1604-1615. (doi:10.2337/db09-0058)
53. Moore B 1906 On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane. Biochemical Journal 1 28-38.
54. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H et al. 1999 Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. PNAS 96 1569-1573. (doi:10.1073/pnas.96.4.1569)
55. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L & Alba LM 2010 Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53 153-159. (doi:10.1007/s00125-009-1515-4)
56. Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G & Creutzfeldt W 1989 Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. Journal of Clinical Endocrinology and Metabolism 69 654-662. (doi:10.1210/jcem-69-3-654)
57. Nyborg NC, Molck AM, Madsen LW & Bjerre Knudsen L 2012 The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 61 1243-1249. (doi:10.2337/db11-0936)
58. Parks M & Rosebraugh C 2010 Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. New England Journal of Medicine 362 774-777. (doi:10.1056/NEJMp1001578)
59. Rebours V, Boutron-Ruault MC, Schnee M, Ferec C, Le Marechal C, Hentic O, Maire F, Hammel P, Ruszniewski P & Levy P 2009 The natural history of hereditary pancreatitis: a national series. Gut 58 97-103. (doi:10.1136/gut. 2008.149179)
60. Roman S, Lin R & Sosa JA 2006 Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107 2134-2142. (doi:10.1002/cncr.22244)
61. Sjolund K, Sanden G, Hakanson R & Sundler F 1983 Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 85 1120-1130.
62. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF & Egan JM 2000 Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 741-748. (doi:10.2337/diabetes.49.5.741)
63. Thulesen J, Hartmann B, Hare KJ, Kissow H, Orskov C, Holst JJ & Poulsen SS 2004 Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53 1145-1150. (doi:10.1136/gut.2003.035212)
64. Tran TT, Medline A & Bruce WR 1996 Insulin promotion of colon tumors in rats. Cancer Epidemiology, Biomarkers & Prevention 5 1013-1015.
65. Tripathy NR, Basha S, Jain R, Shetty S & Ramachandran A 2008 Exenatide and acute pancreatitis. Journal of the Association of Physicians of India 56 987-988.
66. Vilsboll T, Krarup T, Deacon CF, Madsbad S & Holst JJ 2001 Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 609-613. (doi:10.2337/diabetes.50.3. 609)
67. Waser B, Beetschen K, Pellegata NS & Reubi JC 2011 Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94 291-301. (doi:10.1159/000330447)
68. Xia Z, Dickens M, Raingeaud J, Davis RJ & Greenberg ME 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 1326-1331. (doi:10.1126/science.270.5240.1326)
69. Xu G, Stoffers DA, Habener JF & Bonner-Weir S 1999 Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 2270-2276. (doi:10.2337/diabetes.48.12.2270)
70. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA et al. 2010 Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 1114-1117. (doi:10.1038/nature09515)